Trials / Unknown
UnknownNCT04762485
Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia
Humanized Chimeric Antigen Receptor T Cells Against CD7 for Refractory/Relapsed CD7+ Acute Leukemia
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- The First Affiliated Hospital of Soochow University · Academic / Other
- Sex
- All
- Age
- 12 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective,open-label, single center and single arm phase 1/2 study to evaluate the efficacy and safety of T cells expressing humanized CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7 positive acute leukemia.
Detailed description
The patients will receive infusion of CAR T-cells targeting CD7 to confirm the safety and efficacy of CD7 CAR T-Cells in CD7+ relapsed or refractory acute leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Humanized CD7 CAR-T cells | Split intravenous infusion of CD7 CAR-T cells \[dose escalating infusion of (0.5-10)x10\^6 CD7 CAR-T cells/kg |
Timeline
- Start date
- 2021-06-01
- Primary completion
- 2023-02-28
- Completion
- 2024-02-28
- First posted
- 2021-02-21
- Last updated
- 2021-06-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04762485. Inclusion in this directory is not an endorsement.